

## Vaccibody AS Lists on Oslo Stock Exchange's Merkur Market

- *Company is admitted to trading on the electronic trading platform Merkur Market as of October 7, 2020 under the ticker "VACC-ME"*

**Oslo, Norway, October 7, 2020** – Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, announces that its shares have been admitted to trading on the Norwegian trading platform Merkur Market ("Merkur"), owned and operated by Oslo Børs, from today October 7, 2020.

Vaccibody will trade under the ticker "VACC-ME". The Company currently has 283,627,680 outstanding shares of NOK 0.01 each, all of which are registered in the Norwegian Central Securities Depository (VPS) under ISIN NO 0010714785.

The Chair of the Board of Directors, Anders Tuv, comments: "Due to the news flow, Vaccibody has over the past twelve months generated significant interest from both Norwegian and international investors. The list of shareholders has almost tripled during the past year and now counts more than 800 individual shareholders. The registration and fully electronic trading on Merkur is a logical next step for Vaccibody and will further facilitate the transparency of trading in and the liquidity of the Company's shares."

### **About Vaccibody**

Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The Company is using the Vaccibody technology to generate best-in-class therapeutics against cancers and infectious diseases with a high unmet medical need.

Vaccibody is developing cutting-edge, targeted DNA vaccines for clinical use, based on a deep understanding of immunological principles. Vaccibody's vaccines specifically target Antigen Presenting Cells (APC), which are essential for inducing rapid, strong and specific immune responses and elicit efficacious clinical responses. By intelligent design, Vaccibody's vaccines can be tailored to induce the desired immune response profile correlating with protection for each specific disease with any given antigen. Hence, the Vaccibody vaccine platform has the potential to address many disease areas with a high unmet medical need such as cancer and infectious diseases. Vaccibody has collaborations with Roche and Genentech, and Nektar Therapeutics and will pursue further collaborations and strategic partnerships to maximize the value of its technology platform.

Vaccibody's shares are traded on Merkur Market, a trading platform operated and wholly owned by Oslo Børs ASA, the Oslo Stock Exchange.

Further information about the Company may be found at <http://www.vaccibody.com>

**Contact:**

CEO Michael Engsig

Vaccibody AS

Cell: +45 6173 1509

[mengsig@vaccibody.com](mailto:mengsig@vaccibody.com)

**Vaccibody AS**

Oslo Research Park

Gaustadalléen 21

0349 Oslo, Norway